Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure

In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT‑proBNP, a biomarker for heart failure, in patients with HFrEF on top of guideline-directed medical therapy, with a favorable safety and tolerability profile Company continues to advance tovinontrine in a pioneering clinical program targeting PDE9 in heart failure Results from the Cycle Phase 2 […] The post Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure appeared first on Cardurion .